Pain is real. If it is your pain, relief can be life changing. Regenesis Biomedical discovered an underutilized therapy and developed a unique platform that is delivering a solution to help patients manage their pain with a safe, easy to use, non-drug medical device.
Regenesis offers the Provant® Therapy System, an FDA-cleared medical device that is a safe, prescriptive non-drug alternative to opioids.  Regenesis’ customers include health care facilities and providers that serve patients treated in hospitals, rehabilitation centers, outpatient clinics, and by patients self-treating at home.

https://www.azbio.org/regenesis-biomedical-inc-named-arizona-bioscience-company-of-the-year

As Head of Company Sourcing for JLABS, Kara leads the company recruitment and selection process for JLABS including JLABS San Diego, JLABS@QB3 in San Francisco and JLABS@LabCentral in Cambridge/Boston. In this role, Kara is actively building a pipeline of prospects and driving licensee companies through diligence, selection, and joining JLABS. Kara coordinates with the J&J Innovation Centers and J&J Development Corporation to build opportunities and grow relationships between JLABS companies and potential strategic partners.

You probably know someone who is waiting for a cure. Most of us do.  It can take over 15 years and a billion dollars or more to bring a new life-saving or life-changing treatment to the people who are waiting for it,.  Throughout her career, Dr. Brumfield has worked to bring new, safe, and effective treatments to market for patients who are waiting.

https://www.azbio.org/martha-a-brumfield-phd-named-arizona-bioscience-leader-of-the-year

Moderated by Dennis Ford, Founder and CEO of Life Science Nation this panel of  active Life Science investors will explore their thoughts and experiences on what it takes to identify and support a winning life science  investment partnership with Paneists: Neil  Berkley of GSK, Cynthia Ekberg Tsai, and Conrad Plimpton

§  Mara Aspinall, Managing Director of BlueStone Venture Partners, shares insights on the vital role of research in the development and delivery of life changing and life saving innovations at the 2019 AZBio Awards

Laurence Hurley, PhD, is the Howard Schaeffer Chair in Pharmaceutical Sciences at the University of Arizona College of Pharmacy and director of the UA BIO5 College of Pharmacy Drug Discovery and Development Program. He also is a research member of the UA Cancer Center, among other roles. He is the leading authority on the identification of small molecule therapeutic agents that target DNA quadruplexes, which are unique four-stranded DNA structures that control gene expression.

Named 2016 Arizona Bioscience Leader of the Year, Mara Aspinall is a biotech industry executive and healthcare pioneer. Aspinall is President and CEO of HealthCatalysts, a firm dedicated to the growth of new healthcare companies.  Aspinall is also Executive Chairman of GenePeeks, a computational genomics company creating a paradigm shift in genetic testing and personalized medicine.  GenePeeks’ proprietary technology can identify the risk of passing on monogenic disease to progeny pre-conception through data mining the maternal and paternal genomes.  Aspinall is the former President and CEO of Ventana Medical Systems division of Roche, worldwide leader in development and commercialization of tissue-based cancer diagnostics. Mara previously spent 12 years as President of Genzyme Genetics and Genzyme Pharmaceuticals. Genzyme Genetics, set the standard for quality in the diagnostics industry leading the market in prenatal and cancer testing. The business was sold to LabCorp for $1 billion. Aspinall is a member of the Board of Directors of Safeguard Scientifics (NYSE:SFE), Abcam plc (AIM:ABC), Blue Cross Blue Shield Arizona, Castle Biosciences and SenesTech.

More than 25 million Americans have asthma. This includes 7.7 percent of adults and 8.4 percent of children according to 2018 data from the U.S. Centers for Disease Control and Prevention. Dr. Kraft is an internationally renowned physician-scientist who specializes in translational asthma research. She focuses her work on precision medicine therapies to treat severe asthma. Her research has been funded by the National Institutes of Health (NIH) and the American Lung Association for nearly 25 years. As a principal investigator, she currently is in the third year of a 5-year, $7.02 million grant from the National Institute of Allergy and Infectious Diseases, an NIH unit, to study “Dysfunction of Innate Immunity in Asthma,” and in the first year of a 6-year, $2.42 million grant from the National Heart, Lung, and Blood Institute, another NIH unit, for participation in the PrecISE Network, a national research network that evaluates precision medicine approaches for the treatment of severe asthma. She also is principal investigator on an Arizona Biomedical Research Commission grant and co-principal investigator with Lynn Gerald, PhD, MSPH, as the UA is a site for the American Lung Association Clinical Research Centers to evaluate new treatments for asthma and chronic obstructive pulmonary disease (COPD).
https://www.azbio.org/monica-kraft-md-of-the-university-of-arizona-named-arizona-bioscience-researcher-for-the-year

Learning opportunities are all around us. Many of these opportunities are thanks to dedicated educators who work to make them engaging, enlightening and memorable. They help us understand the world we live in today and provide tools we can use to shape our tomorrows. Dr. Marti Lindsey is a great example of an educator who is making a difference here in Arizona and across the Southwest region.

https://www.azbio.org/marti-lindsey-phd-of-the-university-of-arizona-to-be-honored-as-the-michael-a-cusanovich-arizona-bioscience-educator-of-the-year